

**PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes**  
**300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011**

**Wednesday, April 12, 2023 – 12:00 PM – 1:30 PM**

**Present:** Meghan McNelly, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Christopher Hughes, Dr. Carla Huitt, Sandi Zappone

**Absent:** Dr. Mahmood Usman, Dr. Venkateswara Davuluri, Dr. Kolin Good, Dr. Keith Brown

**Non-Voting Members:** Amy Nowacki (Pharmacy), Jason Skaria (Pharmacy Manager), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Tanayja Sams (Pharmacy), George Kimbrow (Clinical Policy Coordinator).

**Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.

**Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:17 PM.

**Next Meeting:** Wednesday, July 12, 2023 – 12:00 PM

**Submitted By:** Shalyn Kline (PHW Pharmacy)

Shalyn Kline, PharmD

**Date:** 7/12/23

**Committee Chair:** \_\_\_\_\_

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
<b>I. Introduction &amp; Call to Order</b>	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	Sandi Zappone is our newest P&T member and is a dual member with PA Health & Wellness			Meghan McNelly
B. Announcements	<p>Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p>	No action required or taken.		Meghan McNelly
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> <li>i. Voting and vote totals</li> <li>ii. Tie breaker</li> <li>iii. Pennsylvania's Review and Approval Process</li> </ul>	No action required or taken.		Meghan McNelly
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
<b>II. Approval of Meeting Minutes</b>	A vote was taken for the approval of the minutes from Q1_2023. No objections were made.	Adoption of Q1_2023 Meeting Minutes recorded as approved		Shalyn Kline
<b>III. Old Business</b>	No old business	No action required or taken.		Shalyn Kline

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

A. Policy Submission Status	There are 0 outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
<b>IV. New Business</b>				
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.			Shalyn Kline
B. Provider Education	A vote was taken for the approval of the Pain Management provider education. No objections were made.	The provider education was Committee approved.		Shalyn Kline
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
D. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary revisions, new policies created, and policies being replaced/retired for all lines of business.	The policy revisions were Committee approved.		Shalyn Kline
E. Complaints and Grievances Review	Shalyn stated that there was 1 determination upheld and 11 overturned. Five of the twelve determinations were for opioids.			Shalyn Kline
F. Drug Utilization Review	Shalyn presented the drug utilization review, noted the numbers are for October-December.  FWA – There were 42 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. No Participants were identified with three or more practices/hospitals prescribing opioids.			Shalyn Kline

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	<p>705 possible participants were identified for inappropriate duration of therapy for PPIs, 143 have already been resolved.</p> <p>194 participants were identified to have an absence of a controller inhaler in asthma, 15 have already been resolved.</p>			
G. PBM Oversight	<p>Corrective Action Plan put in place in Quarter 2 by PA DHS.</p> <p>Internal audit of all Prior Authorizations required by PHW pharmacists including PDL application, correct policy use, correct member/provider letter template, and decision timeline.</p> <p>As of March 2023, the Pharmacy CAP has been closed. The state will continue to monitor denials. We will continue internal audits to ensure compliance.</p> <p>Meghan stated in February of this year the state came for an onsite visit, were current processes were reviewed. They were impressed with the speed in which changes were made from April to June where we were over the 95% threshold. Medications in certain drug classes are to be reviewed more carefully and with more clinical decision making. There is currently 2 cases being discussed between the state Medical Directors and our Medical Directors, as cases can only be denied by a physician.</p>			Jason Skaria/ Meghan McNelly
K. Open Forum	<p>Meghan stated she will be making a change and will be stepping back as the Pharmacy Director and will remain the Quality Director. This will be her last P&amp;T meeting she will run. Meghan has been the director of Pharmacy for 5 years and thanked everyone for their participation.</p>	No action required or taken.		Meghan McNelly
Adjournment	<p>The meeting was adjourned at 12:17 pm</p>	Meeting adjourned		Meghan McNelly

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).